Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Hjärtvagala effekter av GES hos patienter med gastropares och vagalnervverkan i vagusnerven (GES)

28 september 2026 uppdaterad av: Thomas V. Nowak, Indiana University

Hjärtvagala effekter av gastrisk elektrisk stimulering och vagalnervverkan i vagusnerven hos patienter med gastropares

The objective of this study is to determine if Gastric Electrical Stimulation may influence vagal outflow via vagal afferent fibers that terminate in the Central Nervous System.

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Detaljerad beskrivning

All patients who are going to have a GES device implanted, or who already have the device are eligible to be part of the study. They will be followed according to the time point they enter the study and its schedule. The visit procedures will be conducted at the discretion of the investigator dependent on the clinical condition of the subject at that time. The study involves EKG and vagal nerve recordings. Three EKG electrodes will be placed (one on chest and 2 on either arms or legs). Separate electrodes will be placed on the neck overlying the vagus nerves

Baseline (Pre-GES Implantation) Visit:

Subjects who are being seen in clinic for possible gastroparesis and may be a possible candidate for GES later or will be undergoing the GES implantation may have a baseline visit. . The baseline visit can be held either at the time of the clinic visit or before the GES implantation. If the baseline visit occurs on the day of the GES implantation, 2 separate EKGs will be performed, one prior to GES pacemaker device implantation for up to a duration of 5 minutes and the second one after the implantation in the recovery room. This EKG will be performed for a total duration of up to 15 minutes with 5 minute "ON", 5 minutes :OFF" and another 5 minutes in the "ON" position. At the same visit with each EKG recording separate EKG electrode will be placed on the neck overlying the vagus nerve. Vagal nerve recordings will be documented for a total duration of upto 15 minutes with approximately 5 min at "ON", 5 min "OFF" and another 5 min "ON" settings of the stimulator in conjunction with the EKG recordings.

At the baseline visit separate EKG electrodes will also be placed on the neck overlying the vagus nerve and a 5 minute recording will be made in conjunction with the EKG recordings.\ before the implantation.

If the subjects already have the GES device implanted then a baseline visit will not be required. They will be included in the study at the time the consent form is signed and will be followed as needed according to the clinic visit schedule and at the discretion and clinical judgement of the investigator.

Post-GES Implantation Visits:

The subject may be asked at the clinic visits to repeat the EKG and vagal nerve study procedures at the discretion and clinical judgment of the investigator.

EKG electrodes will be placed on the chest and arms/legs, and vagal nerve electrodes will be placed on the neck overlying the vagus nerve. A butterfly catheter is inserted under aseptic conditions into a peripheral vein. Fifteen ml (1 tablespoon) of blood is withdrawn and placed on ice (labeled Baseline). With the subject at rest recordings may be made for upto a total duration of 15- 20 minutes. After 15- 20 minutes of recordings the GES device is then turned "OFF" and recordings will be made for up to 40 minutes. After 40 minutes additional 15 ml (1 tablespoon) of blood is withdrawn after the device has been in the OFF position for 40 minutes (labeled "OFF"). The device is then turned back in the "ON" position with the GES settings either at the original or changed settings from the previous settings based on the clinical judgement of the investigators, The EKG and vagal recordings may be made for up to 15-20 minutes. After 15- 20 minutes in the ON position 15 ml (1 tablespoon) is then withdrawn (labeled "ON". The butterfly catheter is then withdrawn, and a bandage is placed at the venipuncture site. The final setting on the GES will depend on the clinical decision of the investigator based on the subject's symptoms and presentation to the clinic.

Studietyp

Observationell

Inskrivning (Faktisk)

158

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Indiana
      • Indianapolis, Indiana, Förenta staterna, 46202
        • Indiana University Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 90 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

This study will evaluate male and female patients at least 18 years of age, with gastroparesis, who will or have already undergone the implantation of a GES device (Enterra, Medtronic, Minneapolis, MN)

Beskrivning

Inclusion Criteria:

  • At least 18 years of age.
  • Documented diagnosis of gastroparesis.
  • Will undergo implantation of a GES device or already has a GES device implanted

Exclusion Criteria:

  • Pregnancy
  • History of allergic reaction to EKG lead placement adhesives.
  • unable to give informed consent

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: CASE_ONLY
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
GES subjects

male and female patients at least 18 years of age, with gastroparesis, who will or have already undergone the implantation of a GES device

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Determine if GES influences vagal outflow
Tidsram: 2-3 years

To determine if GES may influence vagal outflow via vagal afferent fibers that terminate in the Central Nervous System; EKG electrodes will be placed on the chest, stomach, jugular, and vagas nerves. The purpose of this is to record the effects of the stimulator when on and off. The ECG signals are digitized with an ECG power amplifier, Power Lab by AD Instruments. The digitized signals are analyzed with an ECG software analysis system, Lab Chart. The analysis will look for heart rate variability, total power variability, and frequency variability. This will determine if stimulation has an effect on these levels.

2-3 years

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Release of hormones
Tidsram: 2-3 years

The purpose of this investigation is to determine whether gastric electrical stimulation of the stomach via a surgically implanted stimulation device is associated with gastrointestinal hormone release in human subjects. Blood draws will be obtained in tandem with each of the 3 phases of EKG recordings. The blood samples will be processed and serum will be sent to an IU Lab for Hormone analysis to see if typical hormone levels associated with digestion increase or decrease with the addition/subtraction of the gastric stimulation.

2-3 years
Vagus nerve anatomy
Tidsram: 2-3 years

To optimize the methods for determining electrode placement around the cervical vagus nerve. The development of a method to record and analyze compound action potentials from the vagus nerve will enhance our knowledge of the mechanism of action of VNS in the treatment of gastroparesis.

2-3 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Utredare

  • Huvudutredare: Thomas Nowak, MD, Indiana University

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 november 2012

Primärt slutförande (Faktisk)

16 september 2024

Avslutad studie (Faktisk)

16 september 2024

Studieregistreringsdatum

Först inskickad

6 juni 2014

Först inskickad som uppfyllde QC-kriterierna

6 juni 2014

Första postat (Beräknad)

10 juni 2014

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

1 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

28 september 2026

Senast verifierad

1 augusti 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad produktprodukt

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera